Constrictive-Effusive Pericarditis 

  • Author: D Dirk Bonnema, MD; Chief Editor: Joseph L Fredi, MD   more...
 
Updated: Dec 5, 2011
 

Background

Effusive-constrictive pericarditis is a clinical syndrome characterized by concurrent pericardial effusion and pericardial constriction where constrictive hemodynamics are persistent after the pericardial effusion is removed. The mechanism of effusive-constrictive pericarditis is thought to be visceral pericardial constriction. Pericardial effusions vary in size and age and may be transudative, exudative, sanguineous, or chylous. An effusion persisting for months to years may evolve into effusive-constrictive pericarditis.[1, 2, 3, 4, 5, 6, 7, 8, 9, 10]

The pericardium consists of two layers, a parietal layer and visceral layer. The visceral pericardium is composed of 1 or 2 cell layers of mesothelial cells and adheres closely with the epicardium. The parietal pericardium is separated from the visceral pericardium by a small amount of fluid that serves as a lubricant. Any supraphysiological accumulation of this fluid is identified as a pericardial effusion.[1, 2, 11, 12, 13] In general, a pericardial effusion should be evaluated to determine its etiology and hemodynamic significance.

Patients with effusive-constrictive pericarditis may present with symptoms caused from a limitation of intercardiac end-diastolic volume. These findings are secondary to not only the pericardial effusion but also pericardial constriction. Symptoms, as well as history and physical findings, vary and a moderate-to-large pericardial effusion may occur.

Jugular venous and arterial pressures may be within the reference range, with or without signs of cardiac tamponade. This syndrome can evolve as part of a clinical continuum initiated by pericarditis or a pericardial effusion; thus, its etiologies mirror those of pericarditis, pericardial tamponade, and chronic constrictive pericarditis (see Pericarditis, Constrictive). The hemodynamic definition of this syndrome is the continued elevation of right atrial, end-diastolic right ventricular and left ventricular diastolic pressures after the removal of pericardial fluid returns the pericardial pressure to zero (or near zero).[1, 3, 14]

Recognition of effusive-constrictive pericarditis is clinically important because treatment with pericardiocentesis or a pericardial window may be inadequate as it would not address the visceral pericardium. Rather, a visceral pericardiectomy may be indicated for optimal therapy since it is the visceral pericardium that is constricting.

Importantly, not all cases of effusive-constrictive pericarditis progress to chronic constrictive pericarditis. In some clinical situations, relief from the effusion is obtained by means of pericardiocentesis or a pericardial window, and medical treatment is used to manage the underlying condition. The constriction may be transitory and surgical pericardiectomy may be avoided. These situations usually occur in the first months of a chronic effusion and close monitoring is required.

The effusive-constrictive variant of pericarditis was first described in the 1960s. Hancock popularized this definition of a constrictive physiology with a coexisting pericardial effusion.[3] In 2004, Sagrista-Sauldea et al reported 15 subjects from Barcelona, Spain who were identified as having effusive-constrictive pericarditis.[14] These individuals were among 190 consecutive subjects with clinical tamponade who underwent pericardiocentesis and concurrent catheterization. The etiologies of the effusive-constrictive pericarditis were infectious causes, irradiation, cardiac surgery, and idiopathic. Consistent with Hancock's data, Sagrista-Sauldea reported that most cases were due to idiopathic factors.

Next

Pathophysiology

Constrictive pericarditis and cardiac tamponade both restrict filling of the cardiac chambers, thereby increasing both systemic and pulmonary filling pressures. In tamponade, single forward flow occurs during systole (prominent x descent in atrial pressure tracings), whereas in constriction, a biphasic pressure tracing is greater during diastole (prominent y descent). Patients with effusive-constrictive pericarditis may have tamponadelike pressure tracings, which change to constrictivelike tracings after pericardiocentesis. This is because the visceral pericardium, not the parietal, is constrictive. In rare cases, a loculated effusion may lead to constriction with regional tamponade of 1 or more cardiac chambers. Almost any form of chronic pericardial effusion has the potential to organize into an effusive-constrictive state even though the absolute number of cases is relatively low.[4]

Effusive-constrictive pericarditis may be part of a clinical continuum. Stages of infective pericarditis have been observed that range from acute pericarditis and tamponade with effusion to constrictive pericarditis without effusion. Effusive-constrictive pericarditis is likely a middle phase in this evolution. Therefore, suspicion for this entity should be high in cases of indolent, subacute pericarditis, as well in cases of chronic pericardial effusion.

Previous
Next

Epidemiology

Frequency

United States

Effusive-constrictive pericarditis is a rare disorder. As a complication of pericarditis, pericardial effusion, pericardial tamponade, or chronic constrictive pericarditis, the incidence of effusive-constrictive pericarditis is proportional to the incidence of each of these entities. Cases in the United States are more often secondary to irradiation, cardiac surgery, uremia, or malignancy, or are idiopathic (see Differentials).[6]

International

Effusive-constrictive pericarditis is a rare disorder. As a complication of pericarditis, pericardial effusion, pericardial tamponade, or chronic constrictive pericarditis, the incidence of effusive-constrictive is proportional to the incidence of each of these entities. Cases in the developing countries are more often secondary to infectious causes (eg, tuberculosis) than other causes (see Differentials).[15] In a prospective study of 1184 patients with pericarditis, Sagrista-Sauldea et al reported that 6.9% of 218 patients with tamponade had confirmed effusive-constrictive pericarditis.[14]

Mortality/Morbidity

  • The mortality of effusive-constrictive disease is directly related to its etiology. For example, patients with metastatic carcinoma in the pericardial space usually have a prognosis much poorer than that of patients with postviral or idiopathic pericardial effusion with constriction.
  • Constrictive physiology increases the risk of morbidity, but no definitive statistics are available.
  • Noncardiac metastatic effusions are often end-stage, with reported mortality rates of 47% and 80% at 3 and 6 months, respectively.

Race

No reported racial predilection exists.

Sex

No reported sex predilection exists.

Age

Since the incidences of many of the diseases that can cause effusive-constrictive pericarditis occur more frequently in older age groups, an age association exists. However, this disease can affect people of any age.

Previous
 
 
Contributor Information and Disclosures
Author

D Dirk Bonnema, MD  Cardiology Fellow, Division of Cardiology, Department of Medicine, Medical University of South Carolina; Research Fellow, Division of Cardiology, Department of Medicine, Medical University of South Carolina

D Dirk Bonnema, MD is a member of the following medical societies: South Carolina Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Terrence X O'Brien, MD, FACC  Professor of Medicine/Cardiology, Director, Clinical Cardiovascular Research, Medical University of South Carolina; Director, Echocardiography Laboratory, Veterans Affairs Medical Center of Charleston

Terrence X O'Brien, MD, FACC is a member of the following medical societies: American College of Cardiology, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, and South Carolina Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Eric Vanderbush, MD, FACC  Chief, Department of Internal Medicine, Division of Cardiology, Harlem Hospital Center; Clinical Assistant Professor of Cardiology, Columbia University College of Physicians and Surgeons

Eric Vanderbush, MD, FACC is a member of the following medical societies: American College of Cardiology and American Heart Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Ronald J Oudiz, MD, FACP, FACC, FCCP  Professor of Medicine, University of California, Los Angeles, David Geffen School of Medicine; Director, Liu Center for Pulmonary Hypertension, Division of Cardiology, LA Biomedical Research Institute at Harbor-UCLA Medical Center

Ronald J Oudiz, MD, FACP, FACC, FCCP is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American College of Physicians, American Heart Association, and American Thoracic Society

Disclosure: Actelion Grant/research funds Clinical Trials + honoraria; Encysive Grant/research funds Clinical Trials + honoraria; Gilead Grant/research funds Clinical Trials + honoraria; Pfizer Grant/research funds Clinical Trials + honoraria; United Therapeutics Grant/research funds Clinical Trials + honoraria; Lilly Grant/research funds Clinical Trials + honoraria; LungRx Clinical Trials + honoraria; Bayer Grant/research funds Consulting

Amer Suleman, MD  Private Practice

Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions

Disclosure: Nothing to disclose.

Chief Editor

Joseph L Fredi, MD  Assistant Professor of Medicine, Director of Acute MI Program, Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center

Joseph L Fredi, MD is a member of the following medical societies: American College of Cardiology and American College of Physicians

Disclosure: Nothing to disclose.

Additional Contributors

Acknowledgment for support for this chapter is given to the Office of Research and Development, Medical Research Service, Ralph H. Johnson Department of Veterans Affairs Medical Center, and the Gazes Cardiac Research Institute, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.

References
  1. Goldstein JA. Cardiac tamponade, constrictive pericarditis, and restrictive cardiomyopathy. Curr Probl Cardiol. Sep 2004;29(9):503-67. [Medline].

  2. Little WC, Freeman GL. Pericardial disease. Circulation. Mar 28 2006;113(12):1622-32. [Medline].

  3. Hancock EW. Subacute effusive-constrictive pericarditis. Circulation. Feb 1971;43(2):183-92. [Medline].

  4. Hoit BD. Management of effusive and constrictive pericardial heart disease. Circulation. Jun 25 2002;105(25):2939-42. [Medline].

  5. Lorell BH. Pericardial diseases. In: Brunwald E, ed. Heart Disease. 5th ed. Philadelphia, PA: WB Saunders; 1997:1496-505.

  6. Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet. Feb 28 2004;363(9410):717-27. [Medline].

  7. Spodick DH, Kumar S. Subacute constrictive pericarditis with cardiac tamponade. Dis Chest. Jul 1968;54(1):62-6. [Medline].

  8. Cameron J, Oesterle SN, Baldwin JC, Hancock EW. The etiologic spectrum of constrictive pericarditis. Am Heart J. Feb 1987;113(2 Pt 1):354-60. [Medline].

  9. Hancock EW. A clearer view of effusive-constrictive pericarditis. N Engl J Med. Jan 29 2004;350(5):435-7. [Medline].

  10. Maisch B. Pericardial diseases, with a focus on etiology, pathogenesis, pathophysiology, new diagnostic imaging methods, and treatment. Curr Opin Cardiol. May 1994;9(3):379-88. [Medline].

  11. Wood P. Chronic constrictive pericarditis. Am J Cardiol. Jan 1961;7:48-61. [Medline].

  12. Spodick DH. The Pericardium: A Comprehensive Textbook. New York, NY: Marcel Dekker; 1997:260-452.

  13. Shabetai R. Pericardial Disease: Etiology, Pathophysiology, Clinical Recognition, and Treatment. New York, NY: Churchill Livingstone; 1995:1024-35.

  14. Sagrista-Sauleda J, Angel J, Sanchez A, et al. Effusive-constrictive pericarditis. N Engl J Med. 2004;350(5):469-75. [Medline].

  15. Zagol B, Minderman D, Munir A, D'Cruz I. Effusive constrictive pericarditis: 2D, 3D echocardiography and MRI imaging. Echocardiography. Nov 2007;24(10):1110-4. [Medline].

  16. Akhter MW, Nuño IN, Rahimtoola SH. Constrictive pericarditis masquerading as chronic idiopathic pleural effusion: importance of physical examination. Am J Med. Jul 2006;119(7):e1-4. [Medline].

  17. Rafailidis PI, Prapas SN, Kasiakou SK, Costeas XF, Falagas ME. Effusive-constrictive calcific pericarditis associated with Streptococcus salivarius. Case report and review of the literature. Cardiol Rev. May-Jun 2005;13(3):113-7. [Medline].

  18. Fowler NO, Manitsas GT. Infectious pericarditis. Prog Cardiovasc Dis. Nov-Dec 1973;16(3):323-36. [Medline].

  19. Maisch B, Seferovic PM, Ristic AD, Erbel R, Rienmüller R, Adler Y. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J. Apr 2004;25(7):587-610. [Medline].

  20. Feigenbaum H, Armstrong W. Pericardial diseases. In: Feigenbaum's Echocardiography. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004:260-9.

  21. Ha JW, Lee JD, Ko YG, Yun M, Rim SJ, Chung N. Images in cardiovascular medicine. Assessment of pericardial inflammation in a patient with tuberculous effusive constrictive pericarditis with 18F-2-deoxyglucose positron emission tomography. Circulation. Jan 3 2006;113(1):e4-5. [Medline].

  22. Maisch B, Pankuweit S, Brilla C, et al. Intrapericardial treatment of inflammatory and neoplastic pericarditis guided by pericardioscopy and epicardial biopsy: results from a pilot study. Clin Cardiol. Jan 1999;22(1 Suppl 1):I17-22. [Medline].

  23. Park GM, Lee JY, Kim YG, Boo SJ, Song JM, Kang DH, et al. Recurrent postoperative effusive-constrictive pericarditis associated with steroid discontinuation. J Cardiovasc Ultrasound. Sep 2009;17(3):102-5. [Medline]. [Full Text].

  24. Olson JE, Ryan MB, Blumenstock DA. Eleven years' experience with pericardial-peritoneal window in the management of malignant and benign pericardial effusions. Ann Surg Oncol. Mar 1995;2(2):165-9. [Medline].

  25. Olsen PS, Sorensen C, Andersen HO. Surgical treatment of large pericardial effusions. Etiology and long- term survival. Eur J Cardiothorac Surg. 1991;5(8):430-2. [Medline].

  26. Kolek M. Effusive-constrictive pericarditis post surgical revision for iatrogenic hemopericardium. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. Mar 2011;155(1):71-4. [Medline].

  27. Okayama S, Soeda T, Seno A, Watanabe M, Nakajima T, Uemura S, et al. Rare concurrence of apical hypertrophic cardiomyopathy and effusive constrictive pericarditis. Open Cardiovasc Med J. 2011;5:99-102. [Medline]. [Full Text].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.